S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
BREAKING: Tiny biotech successfully treats blindness (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
BREAKING: Tiny biotech successfully treats blindness (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Stop Trading Like A Turtle (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
BREAKING: Tiny biotech successfully treats blindness (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
BREAKING: Tiny biotech successfully treats blindness (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Stop Trading Like A Turtle (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
BREAKING: Tiny biotech successfully treats blindness (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
BREAKING: Tiny biotech successfully treats blindness (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Stop Trading Like A Turtle (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
BREAKING: Tiny biotech successfully treats blindness (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
BREAKING: Tiny biotech successfully treats blindness (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Stop Trading Like A Turtle (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Forecast, Price & News

$3.31
+0.25 (+8.17%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.02
$3.45
50-Day Range
$2.72
$3.39
52-Week Range
$2.19
$6.13
Volume
237,586 shs
Average Volume
95,428 shs
Market Capitalization
$62.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Abeona Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,108.5% Upside
$40.00 Price Target
Short Interest
Healthy
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.57mentions of Abeona Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$624 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.38) to ($2.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

144th out of 983 stocks

Pharmaceutical Preparations Industry

59th out of 486 stocks


ABEO stock logo

About Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update
Abeona Therapeutics Q1 2023 Earnings Preview
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Intracranial Therapeutic Market Size By 2030
See More Headlines

ABEO Price History

ABEO Company Calendar

Last Earnings
11/15/2021
Today
6/04/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+564.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-39,700,000.00
Pretax Margin
-2,505.52%

Debt

Sales & Book Value

Annual Sales
$1.07 million
Book Value
$1.00 per share

Miscellaneous

Free Float
18,158,000
Market Cap
$62.16 million
Optionable
Optionable
Beta
1.27

Key Executives

  • Mr. Steven H. Rouhandeh (Age 61)
    Exec. Chairman
  • Dr. Timothy J. Miller (Age 46)
    Pres, Chief Scientific Officer & Director
  • Mr. Jeffrey Blaine Davis (Age 55)
    Chief Operating Officer
  • Mr. Carsten Thiel (Age 54)
    Chief Exec. Officer
  • Mr. Stephen B. Thompson (Age 64)
    Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer













ABEO Stock - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings
or view top-rated stocks.

What is Abeona Therapeutics' stock price forecast for 2023?

2 brokerages have issued 1 year price targets for Abeona Therapeutics' shares. Their ABEO share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,108.5% from the stock's current price.
View analysts price targets for ABEO
or view top-rated stocks among Wall Street analysts.

How have ABEO shares performed in 2023?

Abeona Therapeutics' stock was trading at $3.08 at the beginning of 2023. Since then, ABEO shares have increased by 7.5% and is now trading at $3.31.
View the best growth stocks for 2023 here
.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 366,600 shares, a decrease of 28.4% from the April 30th total of 512,300 shares. Based on an average daily trading volume, of 142,400 shares, the days-to-cover ratio is currently 2.6 days. Approximately 2.0% of the shares of the company are short sold.
View Abeona Therapeutics' Short Interest
.

When is Abeona Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ABEO earnings forecast
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($4.00).

When did Abeona Therapeutics' stock split?

Shares of Abeona Therapeutics reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?
What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.97%), Knott David M Jr (0.90%), ExodusPoint Capital Management LP (0.68%), State Street Corp (0.23%), Renaissance Technologies LLC (0.21%) and Charles Schwab Investment Management Inc. (0.10%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider.
View institutional ownership trends
.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $3.31.

How much money does Abeona Therapeutics make?

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $62.16 million and generates $1.07 million in revenue each year.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.

This page (NASDAQ:ABEO) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -